NMNH, the reduced form of beta-nicotinamide mononucleotide (NMN), is emerging as a superior NAD+ enhancer with significant advantages over NMN. Naturally present in the kidney, NMNH can be rapidly converted into NAD+ within cells, offering a more efficient and potent way to boost NAD+ levels across various tissues. With BONTAC leading the way in NMNH mass production, they are setting new standards in the industry with their patent-grade NMNH (Patent No.: ZL 2024 1 0452498.9) and innovative enzymatic processes.
Superior NAD+ Enhancement
NMNH stands out as a more effective NAD+ enhancer compared to beta-nicotinamide mononucleotide (NMN). The conversion rate and concentration of NMNH into NAD+ in cells are more than twice that of NMN. This superior efficiency makes NMNH an ideal choice for those looking to elevate NAD+ levels in various tissues, promoting better cellular health and function. BONTAC‘s focus on producing high-quality NMNH ensures that users receive the full benefits of this advanced NAD+ precursor.
Pioneering Mass Production
BONTAC is the first to launch mass production of NMNH, setting a new benchmark in the industry. Their commitment to innovation and quality is reflected in their patented NMNH, which is produced using a leading enzymatic process. This advanced production method ensures that BONTAC’s NMNH is of the highest quality, offering consistent and reliable results for those seeking to enhance their NAD+ levels effectively.
Versatile Forms for Various Applications
To cater to different needs, BONTAC offers NMNH in multiple forms, including lyophilized powder, crystallized powder, amorphous, calcium salt, eutectic, and more. This versatility allows for a wide range of applications, making it easier for companies to incorporate NMNH into their products and health regimens. BONTAC’s diverse product offerings ensure that there is an NMNH solution for every requirement.
Conclusion
NMNH is proving to be a game-changer in the field of NAD+ enhancement, offering superior efficiency and potency compared to beta-nicotinamide mononucleotide (NMN). With BONTAC leading the charge in NMNH mass production and patent-grade quality, they are at the forefront of innovation in this space. Their versatile range of NMNH forms further solidifies their position as a leading provider of this powerful NAD+ precursor, making BONTAC the go-to source for those looking to optimize their cellular health.
